(S)-2-tert-butoxycarbonylamino-pentanedioic acid 5-benzyl ester 1-cyclopentyl ester | 219623-96-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-tert-butoxycarbonylamino-pentanedioic acid 5-benzyl ester 1-cyclopentyl ester
• 英文别名: (S)-2-tert-butoxycarbonylaminopentanedioic acid 5-benzyl ester 1-cyclopentyl ester；1-cyclopentyl 5-benzyl (2S)-2-[(tert-butoxycarbonyl)amino] pentanedioate；5-benzyl 1-cyclopentyl N-(tert-butoxycarbonyl)-L-glutamate；5-benzyl-1-cyclopentyl N-(tert-butoxycarbonyl)-L-glutamate；5-benzyl 1-cyclopentyl N-tert-butoxycarbonyl-L-glutamate；5-O-benzyl 1-O-cyclopentyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioate
• CAS: 219623-96-8
• 化学式: C₂₂H₃₁NO₆
• 分子量: 405.491
• InChiKey: HPNRCTWPZDNMMF-SFHVURJKSA-N

物化性质

• 沸点：
  530.6±45.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  90.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-2-tert-butoxycarbonylamino-pentanedioic acid 5-benzyl ester 1-cyclopentyl ester 在 20 % Pd(OH)2/C 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 5.08h， 以85%的产率得到(4S)-4-[(tert-butoxycarbonyl)amino]-5-(cycIopentyloxy)-5-oxopentanoic acid
  参考文献：
  名称：

  [EN] PYRROLO [2, 3-D] PYRIMIDINES AS INHIBITORS OF HSP90
  [FR] PYRROLO[2,3-D]PYRIMIDINES EN TANT QU'INHIBITEURS D'HSP90

  摘要：

  这项发明提供了一种化合物，该化合物为（a）式（I）的吡咯吡嘧啶衍生物或其互变异构体，或（b）其药用可接受盐、N-氧化物、水合物或溶剂化合物：其中R1、R2、R3、R4和W的定义如本文所述。这些化合物在治疗由HSP90介导的疾病以及治疗炎症方面具有用处。

  公开号：

  WO2010043867A1
• 作为产物：
  描述：

  环戊醇 、 N-叔丁氧羰基-L-谷氨酸 5-苄酯 在 4-二甲氨基吡啶 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以71%的产率得到(S)-2-tert-butoxycarbonylamino-pentanedioic acid 5-benzyl ester 1-cyclopentyl ester
  参考文献：
  名称：

  ENZYME AND RECEPTOR MODULATION

  摘要：

  一种α，α-二取代甘氨酸酯和靶细胞内酶或受体活性调节剂的共价结合物，其中共轭物的酯基可被一个或多个细胞内羧酯酶水解为相应的酸，α，α-二取代甘氨酸酯与调节剂结合在远离抑制剂与靶酶或受体之间结合界面的位置，进入细胞并使活性酸水解产物在细胞内积累。

  公开号：

  US20100317865A1

文献信息

• Amino acid derivatives
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20030013725A1

  公开（公告）日：2003-01-16

  A compound of the formula (1): 1 [wherein R 1 is (substituted) alkyl, alkoxy, phenyl, hetero ring etc.; A is bond, CO, SO 2 ; R 2 is H, (substituted) alkyl etc.; D is alkylene etc.; E is COO, OCO, O, S, SO, SO 2 etc.; R 3 is (substituted) alkyl, carbocyclic ring, hetero ring; J is O, NR 16 (R 16 is H, substituted alkyl); R 4 is (substituted) alkyl, carbocyclic ring, hetero ring.] or non-toxic salt thereof, and an N-type calcium channel blocker comprising it as an active ingredient. The compounds of the formula (I) possess an inhibitory action on N-type calcium channel, so they are useful as agent for the prevention and/or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis or epilepsy etc. or agent for the treatment of pain.

  化合物的式子（1）：1[其中R1是（取代）烷基，烷氧基，苯基，杂环等；A是键，CO，SO2；R2是H，（取代）烷基等；D是烷基等；E是COO，OCO，O，S，SO，SO2等；R3是（取代）烷基，环烷基，杂环；J是O，NR16（R16是H，取代烷基）；R4是（取代）烷基，环烷基，杂环。或其非毒性盐，以及作为活性成分的N型钙通道阻滞剂。式（I）的化合物具有对N型钙通道的抑制作用，因此它们可用作预防和/或治疗脑梗死、短暂性脑缺血发作、心脏手术后脑脊髓病、脊髓血管病、应激性高血压、神经症或癫痫等的药物或治疗疼痛的药物。
• ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER
  申请人：Moffat David Festus Charles

  公开号：US20100035901A1

  公开（公告）日：2010-02-11

  The invention provides a compound which is (a) an amino acid derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: wherein R 1 , R 2 , L 1 , Het, A, x, y and W are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90.

  该发明提供了一种化合物，其为（a）公式（I）的氨基酸衍生物或其互变异构体，或（b）其药学上可接受的盐，N-氧化物，水合物或溶剂化物：其中R1，R2，L1，Het，A，x，y和W如此定义。该化合物在治疗由HSP90介导的疾病方面具有用途。
• HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY
  申请人：Davidson Alan Hornsby

  公开号：US20090298924A1

  公开（公告）日：2009-12-03

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers: wherein Y 1 is a bond, —(C═O)—, —S(O 2 )—, —C(═O)O—, —OC(═O)—, —(C═O)NR 3 —, —NR 3 (C═O)—, —S(O 2 )NR 3 —, —NR 3 S(O 2 )—, or —NR 3 (C═O)NR 5 —, wherein R 3 and R 5 are independently hydrogen or optionally substituted (C 1 -C 6 )alkyl, L 1 is a divalent radical of formula -(Alk 1 ) m (O) n (Alk 2 ) p — wherein m, n, p, Alk 1 , Alk 2 and Q are as defined in the claims; z is 0 or 1; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker]- represents a divalent linker radical; R is a radical of formula (X) or (Y): wherein R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R 4 is hydrogen; or optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, aryl(C 1 -C 6 alkyl)-, heteroaryl, heteroaryl(C 1 -C 6 alkyl)-, —(C═O)R 3 , —(C═O)OR 3 , or —(C═O)NR 3 wherein R 3 is hydrogen or optionally substituted (C 1 -C 6 )alkyl, C 3 -C 7 cycloalkyl, aryl, aryl(C 1 -C 6 alkyl)-, heteroaryl, or heteroaryl(C 1 -C 6 alkyl)-; R 4 1 is hydrogen or optionally substituted C 1 -C 6 alkyl; and B is a monocyclic heterocyclic ring of 5 or 6 ring atoms wherein R 1 is linked to a ring carbon adjacent the ring nitrogen shown, and ring B is optionally fused to a second carbocyclic or heterocyclic ring of 5 or 6 ring atoms in which case the bond shown intersected by a wavy line may be from a ring atom in said second ring;

  式(I)的化合物是组蛋白去乙酰化酶活性的抑制剂，可用于治疗癌症等疾病：其中Y1是键，—(C═O)—、—S(O2)—、—C(═O)O—、—OC(═O)—、—(C═O)NR3—、—NR3(C═O)—、—S(O2)NR3—、—NR3S(O2)—或—NR3(C═O)NR5—，其中R3和R5分别是氢或可选取代的（C1-C6）烷基，L1是式-(Alk1)m(O)n(Alk2)p-的二价基团，其中m、n、p、Alk1、Alk2和Q如权利要求所定义；z为0或1；A代表可选取代的单环、双环或三环碳环或杂环系统；-[链接体]-代表二价的连接基团；R是式(X)或(Y)的基团：其中R1是羧酸基（—COOH），或可由一个或多个细胞内羧酸酯酶酶解为羧酸基的酯基；R4是氢；或可选取代的C1-C6烷基、C3-C7环烷基、芳基、芳基(C1-C6烷基)-、杂环芳基、杂环芳基(C1-C6烷基)-、—(C═O)R3、—(C═O)OR3或—(C═O)NR3，其中R3是氢或可选取代的（C1-C6）烷基、C3-C7环烷基、芳基、芳基(C1-C6烷基)-、杂环芳基或杂环芳基(C1-C6烷基)-；R41是氢或可选取代的C1-C6烷基；B是由5个或6个环原子组成的单环杂环，其中R1与所示的环氮相邻的环碳相连，并且环B可选择与第二个由5个或6个环原子组成的碳环或杂环融合，此时由波浪线相交的键可能来自于所述第二个环中的一个环原子。
• Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase
  申请人：Moffat David Festus Charles

  公开号：US20100069473A1

  公开（公告）日：2010-03-18

  Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: wherein R 7 is hydrogen or optionally substituted (C 1 -C 6 )alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is a radical of formula R-L 1 -Y 1 —(CH 2 ) z —, wherein: z is 0 or 1; R is a radical of formula (X) or (Y) R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R 6 is hydrogen, or optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl or heteroaryl or —(C═O)R 3 , —(C═O)OR 3 , or —(C═O)NR 3 wherein R 3 is hydrogen or optionally substituted (C 1 -C 6 )alkyl; Y 1 is a bond, —(C═O)—, —S(O 2 )—, —C(═O)O—, —OC(═O)—, —(C═O)NR 3 —, —NR 3 (C═O)—, —S(O 2 )NR 3 —, —NR 3 S(O 2 )—, or —NR 3 (C═O)NR 4 —, wherein R 3 and R 4 are independently hydrogen or optionally substituted (C 1 -C 6 )alkyl, L 1 is a divalent linker radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n, p, Q, Alk 1 and Alk 2 are as defined in the claims.

  化合物的化学式为（IA）或（IB），可抑制IkB激酶（IKK）活性，用于治疗自身免疫和炎症性疾病：其中R7是氢原子或选择性取代（C1-C6）烷基；环A是一个由5-13个环原子组成的选择性取代芳基或杂环芳基环；Z是一个由R-L1-Y1—(CH2)z—的基团，其中：z为0或1；R是由（X）或（Y）的化学式的基团；R1是羧酸基（—COOH），或者是一个可以被一个或多个细胞内酯酶水解成羧酸基的酯基；R6是氢原子，或选择性取代的C1-C6烷基，C3-C7环烷基，芳基或杂环芳基或—(C═O)R3，—(C═O)OR3或—(C═O)NR3，其中R3是氢原子或选择性取代的（C1-C6）烷基；Y1是一个化学键，—(C═O)—，—S(O2)—，—C(═O)O—，—OC(═O)—，—(C═O)NR3—，—NR3(C═O)—，—S(O2)NR3—，—NR3S(O2)—或—NR3(C═O)NR4—，其中R3和R4分别独立地是氢原子或选择性取代的（C1-C6）烷基；L1是一个由式子-(Alk1)m(Q)n(Alk2)p-组成的二价连接基团，其中m，n，p，Q，Alk1和Alk2在权利要求中定义。
• Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity
  申请人：Chroma Therapeutics Ltd.

  公开号：US07973181B2

  公开（公告）日：2011-07-05

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers: wherein Y1 is a bond, —(C═O)—, —S(O2)—, —C(═O)O—, —OC(═O)—, —(C═O)NR3—, —NR3(C═O)—, —S(O2)NR3—, —NR3S(O2)—, or —NR3(C═O)NR5—, wherein R3 and R5 are independently hydrogen or optionally substituted (C1-C6)alkyl, L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p wherein m, n, p, Alk1, Alk2 and Q are as defined in the claims; z is 0 or 1; A represents an optionally substituted mono-, bi— or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker]- represents a divalent linker radical; R is a radical of formula (X) or (Y): wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R4 is hydrogen; or optionally substituted C1-C6 alkyl, C3-C7cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, heteroaryl(C1-C6 alkyl)-, —(C═O)R3, —(C═O)OR3, or —(C═O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, or heteroaryl(C1-C6 alkyl)-; R41 is hydrogen or optionally substituted C1-C6 alkyl; and B is a monocyclic heterocyclic ring of 5 or 6 ring atoms wherein R1 is linked to a ring carbon adjacent the ring nitrogen shown, and ring B is optionally fused to a second carbocyclic or heterocyclic ring of 5 or 6 ring atoms in which case the bond shown intersected by a wavy line may be from a ring atom in said second ring.

  式(I)的化合物是组蛋白去乙酰化酶活性的抑制剂，可用于治疗癌症等疾病：其中Y1是键，-(C═O)-，-S(O2)-，-C(═O)O-，-OC(═O)-，-(C═O)NR3-，-NR3(C═O)-，-S(O2)NR3-，-NR3S(O2)-或-NR3(C═O)NR5-，其中R3和R5独立地为氢或可选取代的（C1-C6）烷基，L1是式-(Alk1)m(Q)n(Alk2)p的二价基团，其中m，n，p，Alk1，Alk2和Q如权利要求中所定义；z为0或1；A代表可选取代的单、双或三环碳环或杂环；-[连接基]-表示二价连接基团；R是式(X)或(Y)的基团：其中R1是羧酸基（-COOH），或可由一个或多个细胞内羧酸酯酶酶解为羧酸基的酯基；R4是氢；或可选取代的C1-C6烷基，C3-C7环烷基，芳基，芳基（C1-C6烷基）-，杂环芳基，杂环芳基（C1-C6烷基）-，-(C═O)R3，-(C═O)OR3或-(C═O)NR3，其中R3为氢或可选取代的（C1-C6）烷基，C3-C7环烷基，芳基，芳基（C1-C6烷基）-，杂环芳基或杂环芳基（C1-C6烷基）-；R41为氢或可选取代的C1-C6烷基；B为5或6个环原子的单环杂环，其中R1连接到所示的环氮旁的环碳，环B可选择与第二个5或6个环原子的碳环或杂环融合，在这种情况下，用波浪线相交的键可以来自所述第二个环中的环原子。